Importance of therapeutic drug monitoring of anticonvulsants : An overview;Bedeutung der Serumkonzentrationen von Antikonvulsiva : Aktuelle Übersicht

Zeitschrift fur Epileptologie

Volumn 24, Issue 1, 2011, Pages 6-11

  Steinhoff, B J ^a   Froscher W ^b  

^a EPILEPSIEZENTRUM KORK   (Germany)

^b Epilepsiezentrum Bodensee   (Germany)

Author keywords

Anticonvulsants, administration and dosage; Anticonvulsants, adverse effects; Dose response relationship; Epilepsy; Patient compliance

Indexed keywords

ANTICONVULSIVE AGENT;

ANALYTIC METHOD; ANTICONVULSANT THERAPY; ARTICLE; BODY FLUID; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; EPILEPSY; HUMAN; SERUM;

EID: 79953056461     PISSN: 16176782     EISSN: 16100646     Source Type: Journal    
DOI: 10.1007/s10309-010-0148-4     Document Type: Article

References (25)

1. Ben-Menachem E (2003) Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 4:2079-2088 (Pubitemid 37408119)
2. Besag FM, Berry DJ, Pool F et al (1998) Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 39:183-187 (Pubitemid 28074354)
3. Buchthal F, Svensmark O (1971) Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects. Psychiatr Neurol Neurochir 74:117-136
4. Fröscher W (2008) Tabelle 6. In: Fröscher W, Blankenhorn V, May TH et al (Hrsg) Pharmakotherapie der Epilepsien. Tabellarische Darstellung unter besonderer Berücksichtigung der Pharmakokinetik, 4. vollst. überarb. u. erw. Aufl. Schattauer, Stuttgart, S 39-59
5. Fröscher W, Eichelbaum M, Gugler R et al (1981) A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol 224:193-201 (Pubitemid 11217476)
6. Fröscher W, Schier KR, Hoffmann M et al (2005) Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 7:237-248 (Pubitemid 41392424)
7. Jürges U, Steinhoff BJ (2011) Therapeutisches Drugmonitoring von Antiepileptika. Z Epileptol, doi 10.1007/s10309-010-0150-x
8. Patsalos PN, Berry DJ, Bourgeois BF et al (2008) Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239-1276 (Pubitemid 351991390)
9. Perucca E (2000) Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 38:191-204 (Pubitemid 30156621)
10. Pisani F, Oteri G, Russo MF et al (1999) The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40:1141-1146 (Pubitemid 29372631)
11. Rambeck B (2008) Tabelle 7. In: Fröscher W, Blankenhorn V, May TH et al (Hrsg) Pharmakotherapie der Epilepsien. Tabellarische Darstellung unter besonderer Berücksichtigung der Pharmakokinetik, 4. vollst. überarb. u. erw. Aufl. Schattauer, Stuttgart, S 60-61
12. Rambeck B, May TW (2008) Tabelle 8. In: Fröscher W, Blankenhorn V, May TH et al (Hrsg) Pharmakotherapie der Epilepsien. Tabellarische Darstellung unter besonderer Berücksichtigung der Pharmakokinetik, 4. vollst. überarb. u. erw. Aufl. Schattauer, Stuttgart, S 62-66
13. Richens A (1975) Quality control of drug estimations. Acta Neurol Scand Suppl 60:81-84
14. Rowan AJ, Meijer JW, Beer-Pawlikowski N de et al (1983) Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 40:797-802 (Pubitemid 14204322)
15. Sabers A, Tomson T (2009) Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol 22:157-161
16. Sisodiya SM, Sander JW, Patsalos PN (2002) Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 48:217-219 (Pubitemid 34252906)
17. Stefan H (1999) Epilepsien. Diagnose und Behandlung, 3. vollst. überarb. u. erw. Aufl. Thieme, Stuttgart
18. Steinhoff BJ (2004) Nebenwirkungen der Antiepileptika. In: Fröscher W, Hufnagel A, Vassella F (Hrsg) Die Epilepsien. Grundlagen - Klinik - Behandlung, 2. Aufl. Schattauer, Stuttgart, S 564-602
19. Steinhoff BJ (2005) Der Epilepsiepatient in der Praxis. ComMed, Basel
20. Steinhoff BJ, Runge U, Witte OW et al (2009) Substitution of anticonvulsant drugs. Ther Clin Risk Manag 5:449-457
21. Svensmark O, Buchthal F (1964) Diphenylhydantoin and phenobarbital. Serum levels in children. Am J Dis Child 108:82-87
22. Thomson AH, Brodie MJ (1992) Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 23:216-230
23. Wolf P (1991) Antiepileptika haben keinen therapeutischen Bereich. Dtsch Med Wochenschr 116:631-633
24. Woo E, Chan YM, Yu YL et al (1988) If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 29:129-139 (Pubitemid 18094821)
25. Woodbury DM, Penry JK, Schmidt D (Hrsg) (1972) Antiepileptic drugs. Raven, New York